TNFSF11 and tenosynovial giant cell tumor, diffuse type: However, since its approval, only 0.4% of patients with TGCT in the US have been treated with pexidartinib [53] and other systemic therapies have been studied but are not specifically approved for the treatment of TGCT, such as anti-cytokine biologics and RANKL inhibitors [54, 55].